Skip to main content
Menu
ABOUT US
COMPANY OVERVIEW
MANAGEMENT TEAM
BOARD OF DIRECTORS
PARTNERSHIPS
PIPELINE
OUR PIPELINE
Pemvidutide
HepTcellâ„¢
INVESTORS
OVERVIEW
PRESS RELEASES
PRESS RELEASES
PHARMATHENE, INC. HISTORICAL PRESS RELEASES
IN THE NEWS
EVENTS AND PRESENTATIONS
STOCK INFORMATION
STOCK QUOTE & CHART
HISTORICAL PRICE LOOKUP
INVESTMENT CALCULATOR
ANALYST COVERAGE
GOVERNANCE
DOCUMENTS & CHARTERS
MANAGEMENT TEAM
BOARD OF DIRECTORS
COMMITTEE COMPOSITION
FINANCIALS
SEC FILINGS
ANNUAL REPORTS
INVESTOR RESOURCES
IR CONTACT
EMAIL ALERTS
CAREERS
CONTACT US
OUR FOCUS
Developing next generation peptide therapeutics for obesity and liver disease
OUR PROGRAMS
Peptide-Based Therapeutics for Obesity and Liver Diseases
OUR PIPELINE
Our diverse pipeline includes treatments for obesity, NASH (Pemvidutide), and chronic Hepatitis B (HepTcell™).
OBESITY AND LIVER THERAPIES
Pemvidutide
HepTcell™
VIEW PIPELINE
Close Menu
ABOUT US
COMPANY OVERVIEW
MANAGEMENT TEAM
BOARD OF DIRECTORS
PARTNERSHIPS
PIPELINE
OUR PIPELINE
Pemvidutide
HepTcellâ„¢
INVESTORS
OVERVIEW
PRESS RELEASES
PRESS RELEASES
PHARMATHENE, INC. HISTORICAL PRESS RELEASES
IN THE NEWS
EVENTS AND PRESENTATIONS
STOCK INFORMATION
STOCK QUOTE & CHART
HISTORICAL PRICE LOOKUP
INVESTMENT CALCULATOR
ANALYST COVERAGE
GOVERNANCE
DOCUMENTS & CHARTERS
MANAGEMENT TEAM
BOARD OF DIRECTORS
COMMITTEE COMPOSITION
FINANCIALS
SEC FILINGS
ANNUAL REPORTS
INVESTOR RESOURCES
IR CONTACT
EMAIL ALERTS
CAREERS
CONTACT US